Is CureVac N.V. (CVAC) a Buy, Sell, or Hold?
CureVac N.V.
NASDAQ:CVAC
$4.66 USD
$0 (0.0%)
- Volume
- 728.78K
- Average Volume
- 1.17M
- Market Capitalization
- $1.05B
- P/E Ratio
- 5.66
- Dividend Yield
- 0.00%
- Price Target
- $21.00
- Year High
- $5.72
- Year Low
- $2.48
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.70
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Alexander Zehnder |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CVAC |
| CUSIP | N2451R105 |
| CIK | 0001809122 |
| Web | https://www.curevac.com |
| Phone | 49 7071 9883 0 |
| Currency | USD |
| Employees | 825 |
| Country | DE |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.70 |
| Quick Ratio | 3.69 |
| Cash Ratio | 1.76 |
Sales & Book Value
| Annual Sales | $535.18M |
| Price / Sales | 16.31 |
| Cash Flow | -0.25 |
| Price / Cash Flow | -16.40 |
| Price / Book | 1.05 |
Price Target and Rating
| Average Stock Price Forecast | $21.00 |
| High Stock Price Forecast | $37.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -77.81% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.72 |
| Trailing P/E Ratio | 5.66 |
| PEG Ratio | 0.40 |
| P/E Growth | 0.40 |
| Net Income | $162.19M |
| Net Margin | 287.15% |
| Pretax Margin | 348.24% |
| Return on Equity | 23.04% |
| Return on Assets | 14.19% |
Financials Score
| AltmanZ Score | 1.74 |
| Piotroski Score | 3.00 |
| Working Capital | 636.94M |
| Total Assets | 1.14B |
| Ebit | 163.58M |
| Market Cap | 919.72M |
| Total Liabilities | 267.39M |
Poll Results
About CureVac N.V. (NASDAQ:CVAC) Stock
CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine ... initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.
CureVac sues Moderna for patent infringement over COVID-19 vaccines
2026-04-24 16:52:11
German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to messenger RNA (mRNA) technology.
Frequently Asked Questions
-
What is the current CureVac N.V. (CVAC) stock price?
-
CureVac N.V.(NASDAQ:CVAC) stock price is $4.66 in the last trading session. During the trading session, CVAC stock reached the peak price of $5.72 while $2.475 was the lowest point it dropped to. The percentage change in CVAC stock occurred in the recent session was 0.0% while the dollar amount for the price change in CVAC stock was $0.
-
CVAC's industry and sector of operation?
-
The NASDAQ listed CVAC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CVAC?
-
Ulrike Gnad-Vogt | Senior Vice President & Area Head of Oncology
Axel-Sven Malkomes | Chief Financial Officer & Member of Executive Board
Thaminda Ramanayake | Chief Business Officer & Member of Executive Board
Alexander Zehnder | Chief Executive Officer, MD & Member of Management Board
Malte Greune | Chief Operating Officer, Member of Management Board & MD -
How many employees does CVAC have?
-
Number of CVAC employees currently stands at 825. CVAC operates from Friedrich-Miescher-Strasse 15, Tübingen, None 72076, DE.
-
Link for CVAC official website?
-
Official Website of CVAC is: https://www.curevac.com
-
How do I contact CVAC?
-
CVAC could be contacted at phone #49 7071 9883 0 and can also be accessed through its website. CVAC operates from Friedrich-Miescher-Strasse 15, Tübingen, None 72076, DE.
-
How many shares of CVAC are traded daily?
-
The average number of CVAC shares traded daily for last 3 months was 1.17M.
-
What is the market cap of CVAC currently?
-
The market value of CVAC currently stands at $1.05B with its latest stock price at $4.66